Phase III Study of Sunitinib Malate (SU11248) Versus Interferon-α as First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma
- 1 June 2006
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 5 (1), 23-25
- https://doi.org/10.1016/s1558-7673(11)70151-3
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)Journal of Clinical Oncology, 2006
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJAMA, 2006
- Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248Molecular Cancer Therapeutics, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoBlood, 2003